Advertisement
New Zealand markets close in 2 hours 47 minutes
  • NZX 50

    11,872.44
    +69.16 (+0.59%)
     
  • NZD/USD

    0.5949
    +0.0015 (+0.25%)
     
  • NZD/EUR

    0.5550
    +0.0009 (+0.16%)
     
  • ALL ORDS

    7,938.90
    +1.00 (+0.01%)
     
  • ASX 200

    7,685.80
    +2.30 (+0.03%)
     
  • OIL

    83.30
    -0.06 (-0.07%)
     
  • GOLD

    2,329.80
    -12.30 (-0.53%)
     
  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     
  • DAX

    18,137.65
    +276.85 (+1.55%)
     
  • Hang Seng

    17,003.12
    +174.19 (+1.04%)
     
  • NIKKEI 225

    38,312.73
    +760.57 (+2.03%)
     
  • NZD/JPY

    92.0050
    +0.2390 (+0.26%)
     

Why Abiomed’s Product Pipeline Looks Promising

Why Abiomed’s Product Pipeline Looks Promising

Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.